Select all docs (Max 200)
Narrow Results:
Publication Year
Medical Subject
- Adolescent 29
- Adverse Drug Reaction Reporting Systems 16
- Airports 20
- Betacoronavirus 24
- Betacoronavirus/genetics 76
- Cause of Death 100
- Child 49
- Child, Preschool 16
- Clinical Laboratory Information Systems 55
- Clinical Laboratory Services 57
- Clinical Laboratory Techniques 659
- Communicable Disease Control 102
- Communicable Diseases, Emerging 69
- Communicble Disease Control 258
- Community Health Services 35
- Community Participation 37
- Contact Tracing 25
- Containment of Biohazards 34
- Coronavirus 121
- Coronavirus Infections 2310
- Coronavirus Infections/complications 45
- Coronavirus Infections/diagnosis 730
- Coronavirus Infections/epidemiology 24
- Coronavirus Infections/mortality 30
- Coronavirus Infections/prevention & control 502
- Coronavirus Infections/prevention &control 46
- Coronavirus Infections/transmission 16
- COVID-19 3208
- COVID-19 Serological Testing 19
- COVID-19 Testing 177
- COVID-19 Vaccines 311
- COVID-19 Vaccines/adverse effects 23
- COVID-19/complications 49
- COVID-19/diagnosis 16
- COVID-19/genetics 76
- COVID-19/mortality 30
- COVID-19/prevention & control 158
- Death Certificates 33
- Diagnostic Tests, Routine 619
- Disaster Planning 36
- Disease Notification 80
- Disease Outbreaks 193
- Ethnicity 42
- Family Characteristics 26
- Forecasting 89
- Gene-Environment Interaction 16
- Genome, Viral 21
- Genomics 96
- Global Health 133
- GRADE Approach 29
- Healthcare Disparities 38
- Health Communication 16
- Health Equity 26
- Health Facilities 25
- Health Personnel 31
- Health Services Accessibility 17
- Health Status Disparities 38
- Heart Diseases/mortality 30
- Hospitalization 68
- Humans 90
- Immunization, Secondary 62
- Immunization Programs 27
- Infant, Newborn 18
- Infection Control 24
- Inflammation 54
- Laboratories 686
- Local Government 41
- Mass Screening 19
- Mortality 305
- Neoplasms/mortality 30
- Pandemics 2137
- Patients 29
- Patient Safety 45
- Pneumonia 45
- Pneumonia, Viral 117
- Pregnancy 27
- Public Health 75
- Public Health Practice 607
- Public Health Surveillance 131
- Public Policy 30
- Quarantine 26
- Racial Groups 39
- Residence Characteristics 19
- Respiratory Tract Infections 64
- Respiratory Tract Infections/diagnosis 24
- Risk Assessment 18
- Risk Reduction Behavior 19
- Safety 41
- SARS-CoV-2 193
- Schools 21
- Serologic Tests 304
- Severity of Illness Index 89
- Ships 49
- Signs and Symptoms 34
- Specimen Handling 34
- Travel 102
- Vaccination 286
- Viral Vaccines 142
- Vital Statistics 100
- Workforce 22
Personal Author
- Adams, Jerome 2
- Adhikari, Bishwa B. 1
- Aguilar-Gaxiola, Sergio 1
- Agyemang, C. 1
- Airhihenbuwa, C.O. 1
- Alberti, Philip M. 1
- Alimchandani, Meghna 1
- Allen, Krisandra 1
- Anderson, Nancy 1
- Anderson, Nancy L. 3
- Anderson, Steve 1
- Armstrong, Gregory L. 1
- Atmar, Robert L. 1
- Bell, Beth P. 17
- Bergeri, Isabel 1
- Bermudez, Madeline 1
- Biggerstaff, Matthew; 1
- Blumenthal, Roger Scott 1
- Braithwaite, Ronald 1
- Bratberg, Jeffrey 1
- Brian, Zachary 1
- Brisolara, Kari Fitzmorris 1
- Britton, Amadea 1
- Brooks, John T. 1
- Brownlee, Ian G. 1
- Bufka, Lynn F. 1
- Burse, Nakeitra 1
- Butler, Jay C. 2
- Calise, Tamara Vehige 1
- Calo, William A. 1
- Campbell, Angela 1
- Campbell, Ellsworth 1
- Carter, Chenita White 1
- Castaneda, Manuel J. 1
- Castrucci, Brian C. 1
- Centers for Disease Control and Prevention (U.S.).Office of Genomics and Precision Public Health. 2
- Cetron, Martin S. 6
- Chaitram, Jasmine 45
- Chamberland, Mary E. 1
- Charles, Myrna 1
- Chatham-Stephens, Kevin 2
- Chatham-Stephens, Kevin C. 1
- Cheney, Anlan 1
- Chengane, Sabrine 1
- Clark, Thomas A. 1
- Cohn, Amanda C. 2
- Daley, Matt F. 4
- Daley, Matthew F. 23
- Das, Rituparna 4
- Dooling, Kathleen 14
- Douoguih, Macaya 2
- Dubovsky, Filip 2
- Fink, Doran 2
- Fleming-Dutra, Katherine E. 4
- Fulton, Paul 4
- Gargano, Julia W. 4
- Gruber, William 2
- Hall, Elisha 6
- Hause, Anne M. 3
- Havers, Fiona P. 2
- Haynes, Ben 5
- Haynes, Benjamin 6
- Hopkins, Robert 2
- Hopkins, Robert H. 12
- Jones, Jefferson 3
- Kharbanda, Elyse O. 2
- Klein, Nicola P. 6
- Lee, Grace M. 11
- Lehnertz, Nicholas 2
- Link-Gelles, Ruth 9
- Mbaeyi, Sarah A 2
- Mbaeyi, Sarah A. 3
- Messonnier, Nancy E. 21
- Miller, Jacqueline M. 4
- Morrison, Shatavia S. 2
- Moulia, Danielle 2
- Oliver, Sara 3
- Oliver, Sara E. 37
- Oster, Matthew E. 2
- Panagiotakopoulos, Lakshmi 2
- Peacock, Georgina 2
- Priddy, Frances 2
- Prosser, Lisa A. 3
- Redfield, Robert 2
- Rosenblum, Hannah 2
- Routh, Janell 2
- Saydah, Sharon 3
- Scobie, Heather 2
- Scobie, Heather 2
- Shimabukuro, Tom T. 22
- Slayton, Rachel B. 2
- Stokley, Shannon 2
- Su, John R. 4
- Talbot, H. Keipp 8
- Taylor, Christopher A. 2
- Thornburg, Natalie J. 4
- Twentyman, Evelyn 6
- Wallace, Megan 11
- Weigand, Michael 4
- Wharton, Melinda 2
Corporate Author
- Association of State and Territorial Health Officials (U.S.) 25
- AstraZeneca (Firm) 1
- Baylor College of Medicine. 1
- BioNTech SE 2
- Burmese American Community Institute. 1
- CDC COVID-19 Emergency Response Team. 2
- CDC COVID-19 Immunization Safety Unit. 1
- CDC COVID-19 Public Health Response. Epidemiology Task Force. 1
- CDC COVID-19 Response. 102
- CDC COVID-19 Response Team. 1
- CDC COVID-19 Response Vaccine Task Force. 1
- CDC COVID-19 Vaccine Coordination Unit. 3
- CDC COVID-19 Vaccine Planning Unit. Vaccine Safety Team. 6
- CDC COVID-19 Vaccines Work Group 1
- CDC COVID-19 Vaccine Task Force 1
- CDC COVID-19 Vaccine Task Force. 2
- CDC COVID-19 Vaccine Task Force. Vaccine Safety Team. 14
- CDC Vaccine Task Force. Pediatric Vaccine Planning and Implementation. 1
- CDC Vaccine Task Force. Pediatric Vaccine Planning and Implementation Lead. 1
- Center for Biologics Evaluation and Research (U.S.). Office of Biostatistics & Epidemiology. 1
- Center for Biologics Evaluation and Research (U.S.). Office of Vaccines Research and Review. 2
- Center for State, Tribal, Local and Territorial Support (U.S.) 25
- Center for Surveillance, Epidemiology, and Laboratory Services (U.S.). Division of Laboratory Systems. 50
- Centers for Disease Contro and Prevention (U.S.) 18
- Centers for Disease Control & Prevention (U.S.). COVID-19 Response, Vaccine Task Force. Vaccine Confidence & Demand Team, Insights Unit. 1
- Centers for Disease Control & Prevention (U.S.). COVID-19 Response, Vaccine Task Force. Vaccine Confidence & Demand Team. Insights Unit. 6
- Centers for Disease Control and Presention (U.S.) 17
- Centers for Disease Control and Prevention (U.S.) 257
- Centers for Disease Control and Prevention (U.S.). 2
- Centers for Disease Control and Prevention (U.S.). National Center for Emerging and Zoonotic Infectiou 2
- Centers for Disease Control and Prevention (U.S.). National Center for Emerging and Zoonotic Infectious. DiseasesDivision of Healthcare Quality Promotion 3
- Centers for Disease Control and Prevention (U.S.). Office of Advanced Molecular Detection. 1
- Centers for Disease Control and Prevention (U.S.). Office of Genomics and Precision Public Health. 38
- Centers for Disease Control and Prevention (U.S.).Office of Genomics and Precision Public Health. 36
- Centers for Disease Control and Prevention (U.S.).Office of the Chief Medical Officer. 51
- Centers for Disease Control and Prevention (U.S.). Office of the Chief Medical Officer. 48
- Centers for Disease Control and Prevention (U.S.). Stephen B. Thacker CDC Library 99
- Colorado. Department of Public Health and Environment. Colorado State Public Health Laboratory. 1
- COVID-19 Epidemiology Task Force. 1
- COVID-19 Vaccine Effectiveness Epidemiology Task Force 2
- COVID-19 Vaccine Effectiveness Epidemiology Task Force. 2
- COVID-19 Vaccine Safety Technical (VaST) Work Group. 9
- COVID-19 Vaccine Task Force. 1
- HealthPartners Institute. Vaccine Safety Datalink Team. 2
- Immunization Action Coalition (Saint Paul, Minn.) 10
- Janssen Pharmaceuticals Companies of Johnson & Johnson. 4
- Johns Hopkins Special Coagulation Laboratory. 1
- Kaiser Permanente Vaccine Study Center. 7
- Marshfield Clinic Research Institute. Vaccine Safety Datalink. Immunization Safety Office. 5
- Massachusetts. Department of Public Health. 1
- Minnesota. Department of Health. 2
- Moderna (firm) 8
- Moderna TX, Inc. 2
- National Association of County & City Health Officials (U.S.) 25
- National Center for Chronic Disease Prevention and Health Promotion (U.S.) 1
- National Center for Chronic Disease Prevention and Health Promotion (U.S.). Division of Diabetes Translation. 9
- National Center for Chronic Disease Prevention and Health Promotion (U.S.). Division of Reproductive Health. Emergency Preparedness and Response Team Lead. 1
- National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Global Migration and Quarantine. 3
- National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion. Immunization Safety Office. 3
- National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Immunization Safety Office. 1
- National Center for Health Statistics (U.S.) 305
- National Center for Health Statistics. 3
- National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of HIV/AIDS Prevention. 1
- National Center for Immunization and Respiratory Diseases (U.S.) 16
- National Center for Immunization and Respiratory Diseases (U.S.). Coronavirus and Other Respiratory Viruses Division. RESP-NET Hospitalization Surveillance Team. 1
- National Center for Immunization and Respiratory Diseases (U.S.). Coronavirus and Other Respiratory Viruses Division. Surveillance and Prevention Branch. RESP-NET Hospitalization Surveillance Team. 2
- National Center for Immunization and Respiratory Diseases (U.S.). Coronavirus and Other Respiratory Viruses Division. Vaccine Effectiveness Program. 1
- National Center for Immunization and Respiratory Diseases (U.S.). Coronaviruses and Other Respiratory Viruses Division. Epidemiology Branch. COVID-19 Vaccine Effectiveness Program. 1
- National Center for Immunization and Respiratory Diseases (U.S.). Coronaviruses and Other Respiratory Viruses Division. Epidemiology Branch. Post COVID Conditions-Longer Term Sequelae Team. 1
- National Center for Immunization and Respiratory Diseases (U.S.). Coronaviruses and Other Respiratory Viruses Division. Laboratory Branch. 1
- National Center for Immunization and Respiratory Diseases (U.S.). Coronaviruses and Other Respiratory Viruses Division. Surveillance and Prevention Branch. RESP-NET Hospitalization Surveillance Team 1
- National Center for Immunization and Respiratory Diseases (U.S.). COVID-19 Vaccine Effectiveness Program Lead. 1
- National Center for Immunization and Respiratory Diseases (U.S.). Division of Bacterial Diseases. 1
- National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases. 2435
- National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases. Respiratory Diseases Branch. 1
- National Center for Immunization and Respiratory Diseases (U.S.). Immunization Services Division, 1
- National Center for Immunization and Respiratory Diseases (U.S.). Immunization Services Division. 4
- National Center for Immunization and Respiratory Diseases (U.S.). Influenza Division. 25
- National Center for Immunizations and Respiratory Diseases (U.S.). Coronavirus and Other Respiratory Viruses Division. 1
- National Center for Immunizations and Respiratory Diseases (U.S.). Immunization Services Division. 2
- National Institute of Allergy and Infectious Diseases (U.S.). Vaccine Research Center. 1
- National Network of Public Health Institutes (U.S.) 25
- National Resource Center for Refugees, Immigrants, and Migrants. 9
- Novavax, Inc. 2
- Orange County Public Health Laboratory. 1
- Pfizer Ltd 3
- Pfizer Ltd. 3
- Public Health Agency of Canada. 1
- Stanford University School of Medicine. 1
- Translational Genomics Research Institute. 1
- United States. Advisory Committee on Immunization Practices. 2
- United States. Advisory Committee on Immunization Practices. ACIP COVID-19 Vaccines Work Group. 1
- United States. Advisory Committee on Immunization Practices. COVID-19 Vaccine Safety Technical (VaST) Work Group. 1
- United States. Advisory Committee on Immunization Practices. COVID-19 Vaccines Safety Technical Sub-Group (VaST). 3
- United States. Advisory Committee on Immunization Practices. COVID-19 Vaccines Work Group. 146
- United States. Advisory Committee on Immunization Practices. COVID-19 Vaccines Work Group. Coronavirus and Other Respiratory Viruses Division (Proposed) 1
- United States. Advisory Committee on Immunization Practices. COVID-19 Vaccines Work Group. COVID-19 Vaccine Safety Technical (VaST) Subgroup. 5
- United States. Department of Homeland Security. Cybersecurity and Infrastructure Security Agency. 92
- United States. Food and Drug Administration. 2
- University of Michigan. COVID-19 Vaccination Modeling Team. 3
Place as Subject
- Arizona 1
- Asia 1
- Atlanta, GA 1
- China 27
- Florida 1
- Georgia 1
- Nebraska 1
- New York 1
- North America 1
- United States 1999
Resource Type General
- Journal Article 16
- Moving Image 4
- Newsletter 3
- Pamphlet (or booklet) 2
- Poster 2
- Presentation 297
- Still Image 1824
- Text 1418
- Webpage 287
Resource Type Specific
- Bibliography 172
- Charts, Diagrams, Etc. 1
- Collected Works 1
- Conference Publications 297
- Fact Sheet 69
- Forms 2
- Guideline 154
- Infographic 17
- Instructional Film and Video 4
- Map 1504
- Newsletter 291
- Pamphlet (or booklet) 11
- Poster 303
- Presentation 25
- Press Release 10
- Report 1
- Resource Guide 99
- Statistics 300
- Transcript 14
- Visual Abstract 2
- Webinar 52
- Webpage 4
COVID-19
Select all docs (Max 200)
1 -
20 of 3853 Results
SELECT A RANGE
SELECT A FORMAT
Refine Results
Refine Results:
- Adolescent (29)
- Adverse Drug Reaction Reporting Systems (16)
- Airports (20)
- Betacoronavirus (24)
- Betacoronavirus/genetics (76)
- Cause of Death (100)
- Child (49)
- Child, Preschool (16)
- Clinical Laboratory Information Systems (55)
- Clinical Laboratory Services (57)
- Clinical Laboratory Techniques (659)
- Communicable Disease Control (102)
- Communicable Diseases, Emerging (69)
- Communicble Disease Control (258)
- Community Health Services (35)
- Community Participation (37)
- Contact Tracing (25)
- Containment of Biohazards (34)
- Coronavirus (121)
- Coronavirus Infections (2310)
- Coronavirus Infections/complications (45)
- Coronavirus Infections/diagnosis (730)
- Coronavirus Infections/epidemiology (24)
- Coronavirus Infections/mortality (30)
- Coronavirus Infections/prevention & control (502)
- Coronavirus Infections/prevention &control (46)
- Coronavirus Infections/transmission (16)
- COVID-19 (3208)
- COVID-19 Serological Testing (19)
- COVID-19 Testing (177)
- COVID-19 Vaccines (311)
- COVID-19 Vaccines/adverse effects (23)
- COVID-19/complications (49)
- COVID-19/diagnosis (16)
- COVID-19/genetics (76)
- COVID-19/mortality (30)
- COVID-19/prevention & control (158)
- Death Certificates (33)
- Diagnostic Tests, Routine (619)
- Disaster Planning (36)
- Disease Notification (80)
- Disease Outbreaks (193)
- Ethnicity (42)
- Family Characteristics (26)
- Forecasting (89)
- Gene-Environment Interaction (16)
- Genome, Viral (21)
- Genomics (96)
- Global Health (133)
- GRADE Approach (29)
- Healthcare Disparities (38)
- Health Communication (16)
- Health Equity (26)
- Health Facilities (25)
- Health Personnel (31)
- Health Services Accessibility (17)
- Health Status Disparities (38)
- Heart Diseases/mortality (30)
- Hospitalization (68)
- Humans (90)
- Immunization, Secondary (62)
- Immunization Programs (27)
- Infant, Newborn (18)
- Infection Control (24)
- Inflammation (54)
- Laboratories (686)
- Local Government (41)
- Mass Screening (19)
- Mortality (305)
- Neoplasms/mortality (30)
- Pandemics (2137)
- Patients (29)
- Patient Safety (45)
- Pneumonia (45)
- Pneumonia, Viral (117)
- Pregnancy (27)
- Public Health (75)
- Public Health Practice (607)
- Public Health Surveillance (131)
- Public Policy (30)
- Quarantine (26)
- Racial Groups (39)
- Residence Characteristics (19)
- Respiratory Tract Infections (64)
- Respiratory Tract Infections/diagnosis (24)
- Risk Assessment (18)
- Risk Reduction Behavior (19)
- Safety (41)
- SARS-CoV-2 (193)
- Schools (21)
- Serologic Tests (304)
- Severity of Illness Index (89)
- Ships (49)
- Signs and Symptoms (34)
- Specimen Handling (34)
- Travel (102)
- Vaccination (286)
- Viral Vaccines (142)
- Vital Statistics (100)
- Workforce (22)
- Adams, Jerome (2)
- Adhikari, Bishwa B. (1)
- Aguilar-Gaxiola, Sergio (1)
- Agyemang, C. (1)
- Airhihenbuwa, C.O. (1)
- Alberti, Philip M. (1)
- Alimchandani, Meghna (1)
- Allen, Krisandra (1)
- Anderson, Nancy (1)
- Anderson, Nancy L. (3)
- Anderson, Steve (1)
- Armstrong, Gregory L. (1)
- Atmar, Robert L. (1)
- Bell, Beth P. (17)
- Bergeri, Isabel (1)
- Bermudez, Madeline (1)
- Biggerstaff, Matthew; (1)
- Blumenthal, Roger Scott (1)
- Braithwaite, Ronald (1)
- Bratberg, Jeffrey (1)
- Brian, Zachary (1)
- Brisolara, Kari Fitzmorris (1)
- Britton, Amadea (1)
- Brooks, John T. (1)
- Brownlee, Ian G. (1)
- Bufka, Lynn F. (1)
- Burse, Nakeitra (1)
- Butler, Jay C. (2)
- Calise, Tamara Vehige (1)
- Calo, William A. (1)
- Campbell, Angela (1)
- Campbell, Ellsworth (1)
- Carter, Chenita White (1)
- Castaneda, Manuel J. (1)
- Castrucci, Brian C. (1)
- Centers for Disease Control and Prevention (U.S.).Office of Genomics and Precision Public Health. (2)
- Cetron, Martin S. (6)
- Chaitram, Jasmine (45)
- Chamberland, Mary E. (1)
- Charles, Myrna (1)
- Chatham-Stephens, Kevin (2)
- Chatham-Stephens, Kevin C. (1)
- Cheney, Anlan (1)
- Chengane, Sabrine (1)
- Clark, Thomas A. (1)
- Cohn, Amanda C. (2)
- Daley, Matt F. (4)
- Daley, Matthew F. (23)
- Das, Rituparna (4)
- Dooling, Kathleen (14)
- Douoguih, Macaya (2)
- Dubovsky, Filip (2)
- Fink, Doran (2)
- Fleming-Dutra, Katherine E. (4)
- Fulton, Paul (4)
- Gargano, Julia W. (4)
- Gruber, William (2)
- Hall, Elisha (6)
- Hause, Anne M. (3)
- Havers, Fiona P. (2)
- Haynes, Ben (5)
- Haynes, Benjamin (6)
- Hopkins, Robert (2)
- Hopkins, Robert H. (12)
- Jones, Jefferson (3)
- Kharbanda, Elyse O. (2)
- Klein, Nicola P. (6)
- Lee, Grace M. (11)
- Lehnertz, Nicholas (2)
- Link-Gelles, Ruth (9)
- Mbaeyi, Sarah A (2)
- Mbaeyi, Sarah A. (3)
- Messonnier, Nancy E. (21)
- Miller, Jacqueline M. (4)
- Morrison, Shatavia S. (2)
- Moulia, Danielle (2)
- Oliver, Sara (3)
- Oliver, Sara E. (37)
- Oster, Matthew E. (2)
- Panagiotakopoulos, Lakshmi (2)
- Peacock, Georgina (2)
- Priddy, Frances (2)
- Prosser, Lisa A. (3)
- Redfield, Robert (2)
- Rosenblum, Hannah (2)
- Routh, Janell (2)
- Saydah, Sharon (3)
- Scobie, Heather (2)
- Scobie, Heather (2)
- Shimabukuro, Tom T. (22)
- Slayton, Rachel B. (2)
- Stokley, Shannon (2)
- Su, John R. (4)
- Talbot, H. Keipp (8)
- Taylor, Christopher A. (2)
- Thornburg, Natalie J. (4)
- Twentyman, Evelyn (6)
- Wallace, Megan (11)
- Weigand, Michael (4)
- Wharton, Melinda (2)
- Association of State and Territorial Health Officials (U.S.) (25)
- AstraZeneca (Firm) (1)
- Baylor College of Medicine. (1)
- BioNTech SE (2)
- Burmese American Community Institute. (1)
- CDC COVID-19 Emergency Response Team. (2)
- CDC COVID-19 Immunization Safety Unit. (1)
- CDC COVID-19 Public Health Response. Epidemiology Task Force. (1)
- CDC COVID-19 Response. (102)
- CDC COVID-19 Response Team. (1)
- CDC COVID-19 Response Vaccine Task Force. (1)
- CDC COVID-19 Vaccine Coordination Unit. (3)
- CDC COVID-19 Vaccine Planning Unit. Vaccine Safety Team. (6)
- CDC COVID-19 Vaccines Work Group (1)
- CDC COVID-19 Vaccine Task Force (1)
- CDC COVID-19 Vaccine Task Force. (2)
- CDC COVID-19 Vaccine Task Force. Vaccine Safety Team. (14)
- CDC Vaccine Task Force. Pediatric Vaccine Planning and Implementation. (1)
- CDC Vaccine Task Force. Pediatric Vaccine Planning and Implementation Lead. (1)
- Center for Biologics Evaluation and Research (U.S.). Office of Biostatistics & Epidemiology. (1)
- Center for Biologics Evaluation and Research (U.S.). Office of Vaccines Research and Review. (2)
- Center for State, Tribal, Local and Territorial Support (U.S.) (25)
- Center for Surveillance, Epidemiology, and Laboratory Services (U.S.). Division of Laboratory Systems. (50)
- Centers for Disease Contro and Prevention (U.S.) (18)
- Centers for Disease Control & Prevention (U.S.). COVID-19 Response, Vaccine Task Force. Vaccine Confidence & Demand Team, Insights Unit. (1)
- Centers for Disease Control & Prevention (U.S.). COVID-19 Response, Vaccine Task Force. Vaccine Confidence & Demand Team. Insights Unit. (6)
- Centers for Disease Control and Presention (U.S.) (17)
- Centers for Disease Control and Prevention (U.S.) (257)
- Centers for Disease Control and Prevention (U.S.). (2)
- Centers for Disease Control and Prevention (U.S.). National Center for Emerging and Zoonotic Infectiou (2)
- Centers for Disease Control and Prevention (U.S.). National Center for Emerging and Zoonotic Infectious. DiseasesDivision of Healthcare Quality Promotion (3)
- Centers for Disease Control and Prevention (U.S.). Office of Advanced Molecular Detection. (1)
- Centers for Disease Control and Prevention (U.S.). Office of Genomics and Precision Public Health. (38)
- Centers for Disease Control and Prevention (U.S.).Office of Genomics and Precision Public Health. (36)
- Centers for Disease Control and Prevention (U.S.).Office of the Chief Medical Officer. (51)
- Centers for Disease Control and Prevention (U.S.). Office of the Chief Medical Officer. (48)
- Centers for Disease Control and Prevention (U.S.). Stephen B. Thacker CDC Library (99)
- Colorado. Department of Public Health and Environment. Colorado State Public Health Laboratory. (1)
- COVID-19 Epidemiology Task Force. (1)
- COVID-19 Vaccine Effectiveness Epidemiology Task Force (2)
- COVID-19 Vaccine Effectiveness Epidemiology Task Force. (2)
- COVID-19 Vaccine Safety Technical (VaST) Work Group. (9)
- COVID-19 Vaccine Task Force. (1)
- HealthPartners Institute. Vaccine Safety Datalink Team. (2)
- Immunization Action Coalition (Saint Paul, Minn.) (10)
- Janssen Pharmaceuticals Companies of Johnson & Johnson. (4)
- Johns Hopkins Special Coagulation Laboratory. (1)
- Kaiser Permanente Vaccine Study Center. (7)
- Marshfield Clinic Research Institute. Vaccine Safety Datalink. Immunization Safety Office. (5)
- Massachusetts. Department of Public Health. (1)
- Minnesota. Department of Health. (2)
- Moderna (firm) (8)
- Moderna TX, Inc. (2)
- National Association of County & City Health Officials (U.S.) (25)
- National Center for Chronic Disease Prevention and Health Promotion (U.S.) (1)
- National Center for Chronic Disease Prevention and Health Promotion (U.S.). Division of Diabetes Translation. (9)
- National Center for Chronic Disease Prevention and Health Promotion (U.S.). Division of Reproductive Health. Emergency Preparedness and Response Team Lead. (1)
- National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Global Migration and Quarantine. (3)
- National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion. Immunization Safety Office. (3)
- National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Immunization Safety Office. (1)
- National Center for Health Statistics (U.S.) (305)
- National Center for Health Statistics. (3)
- National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of HIV/AIDS Prevention. (1)
- National Center for Immunization and Respiratory Diseases (U.S.) (16)
- National Center for Immunization and Respiratory Diseases (U.S.). Coronavirus and Other Respiratory Viruses Division. RESP-NET Hospitalization Surveillance Team. (1)
- National Center for Immunization and Respiratory Diseases (U.S.). Coronavirus and Other Respiratory Viruses Division. Surveillance and Prevention Branch. RESP-NET Hospitalization Surveillance Team. (2)
- National Center for Immunization and Respiratory Diseases (U.S.). Coronavirus and Other Respiratory Viruses Division. Vaccine Effectiveness Program. (1)
- National Center for Immunization and Respiratory Diseases (U.S.). Coronaviruses and Other Respiratory Viruses Division. Epidemiology Branch. COVID-19 Vaccine Effectiveness Program. (1)
- National Center for Immunization and Respiratory Diseases (U.S.). Coronaviruses and Other Respiratory Viruses Division. Epidemiology Branch. Post COVID Conditions-Longer Term Sequelae Team. (1)
- National Center for Immunization and Respiratory Diseases (U.S.). Coronaviruses and Other Respiratory Viruses Division. Laboratory Branch. (1)
- National Center for Immunization and Respiratory Diseases (U.S.). Coronaviruses and Other Respiratory Viruses Division. Surveillance and Prevention Branch. RESP-NET Hospitalization Surveillance Team (1)
- National Center for Immunization and Respiratory Diseases (U.S.). COVID-19 Vaccine Effectiveness Program Lead. (1)
- National Center for Immunization and Respiratory Diseases (U.S.). Division of Bacterial Diseases. (1)
- National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases. (2435)
- National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases. Respiratory Diseases Branch. (1)
- National Center for Immunization and Respiratory Diseases (U.S.). Immunization Services Division, (1)
- National Center for Immunization and Respiratory Diseases (U.S.). Immunization Services Division. (4)
- National Center for Immunization and Respiratory Diseases (U.S.). Influenza Division. (25)
- National Center for Immunizations and Respiratory Diseases (U.S.). Coronavirus and Other Respiratory Viruses Division. (1)
- National Center for Immunizations and Respiratory Diseases (U.S.). Immunization Services Division. (2)
- National Institute of Allergy and Infectious Diseases (U.S.). Vaccine Research Center. (1)
- National Network of Public Health Institutes (U.S.) (25)
- National Resource Center for Refugees, Immigrants, and Migrants. (9)
- Novavax, Inc. (2)
- Orange County Public Health Laboratory. (1)
- Pfizer Ltd (3)
- Pfizer Ltd. (3)
- Public Health Agency of Canada. (1)
- Stanford University School of Medicine. (1)
- Translational Genomics Research Institute. (1)
- United States. Advisory Committee on Immunization Practices. (2)
- United States. Advisory Committee on Immunization Practices. ACIP COVID-19 Vaccines Work Group. (1)
- United States. Advisory Committee on Immunization Practices. COVID-19 Vaccine Safety Technical (VaST) Work Group. (1)
- United States. Advisory Committee on Immunization Practices. COVID-19 Vaccines Safety Technical Sub-Group (VaST). (3)
- United States. Advisory Committee on Immunization Practices. COVID-19 Vaccines Work Group. (146)
- United States. Advisory Committee on Immunization Practices. COVID-19 Vaccines Work Group. Coronavirus and Other Respiratory Viruses Division (Proposed) (1)
- United States. Advisory Committee on Immunization Practices. COVID-19 Vaccines Work Group. COVID-19 Vaccine Safety Technical (VaST) Subgroup. (5)
- United States. Department of Homeland Security. Cybersecurity and Infrastructure Security Agency. (92)
- United States. Food and Drug Administration. (2)
- University of Michigan. COVID-19 Vaccination Modeling Team. (3)
- Bibliography (172)
- Charts, Diagrams, Etc. (1)
- Collected Works (1)
- Conference Publications (297)
- Fact Sheet (69)
- Forms (2)
- Guideline (154)
- Infographic (17)
- Instructional Film and Video (4)
- Map (1504)
- Newsletter (291)
- Pamphlet (or booklet) (11)
- Poster (303)
- Presentation (25)
- Press Release (10)
- Report (1)
- Resource Guide (99)
- Statistics (300)
- Transcript (14)
- Visual Abstract (2)
- Webinar (52)
- Webpage (4)
- :National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.2020年5月17日:Coronavirus Disease 2020 (COVID-19) U.S. viral testing data : updated May 17, 2020 [Chinese]2020年5月17日本页面将每日更新。报告数字为...:National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.Jan. 26, 2021 | Coronavirus Disease 2019 (CoVID-19):Updated Jan. 26, 2021:Daley, Matthew F.October 26, 2023 | ACIP meeting COVID-19 Vaccines:01-COVID-Daley-508.pdf:Wallace, MeganOctober 26, 2023 | ACIP meeting COVID-19 Vaccines:03-COVID-Wallace-508.pdf:Stokley, ShannonOctober 26, 2023 | ACIP meeting COVID-19 Vaccines:02-COVID-Stokley-508.pdf:Oliver, Sara E.November 19, 2021 | ACIP meeting COVID-19 Vaccines:06-COVID-Oliver-508.pdf:Shimabukuro, Tom T.November 19, 2021 | ACIP meeting COVID-19 Vaccines:04-COVID-Shimabukuro-508.pdf:Perez, John L.November 19, 2021 | ACIP meeting COVID-19 Vaccines:02-COVID-Perez-508.pdf:Daley, Matthew F.November 19, 2021 | ACIP meeting COVID-19 Vaccines:01-COVID-Daley-508.pdf:Talbot, H. Keipp ;Hopkins, Robert H.November 19, 2021 | ACIP meeting COVID-19 Vaccines:05-COVID-Talbot-508.pdf:Das, RituparnaNovember 19, 2021 | ACIP meeting COVID-19 Vaccines:03-COVID-Das-508.pdf:Oliver, Sara E.June 23, 2022 | ACIP meeting COVID-19 Vaccines:/06-COVID-Oliver-508.pdf:Shimabukuro, Tom T.June 23, 2022 | ACIP meeting COVID-19 Vaccines:03-COVID-Shimabukuro-508.pdf:Saydah, SharonJune 23, 2022 | ACIP meeting COVID-19 Vaccines:02-COVID-Briggs-Hagan-508.pdf:Talbot, H. Keipp ;Hopkins, Robert H.June 23, 2022 | ACIP meeting COVID-19 Vaccines:04-COVID-Talbot-508.pdf:Hall, ElishaJune 23, 2022 | ACIP meeting COVID-19 Vaccines:07-COVID-Hall-508.pdf:Daley, Matthew F.June 23, 2022 | ACIP meeting COVID-19 Vaccines:01-COVID-Daley-508.pdf:Gruber, William C.June 17, 2022 | ACIP meeting COVID-19 Vaccines:Extracted Regulatory slides05-COVID-Gruber-508.pdf:Oliver, Sara E.June 17, 2022 | ACIP meeting COVID-19 Vaccines:06-COVID-Oliver-508.pdf:Link-Gelles, RuthJune 17, 2022 | ACIP meeting COVID-19 Vaccines:03-COVID-Link-Gelles-508.pdf
Exit Notification/Disclaimer Policy
Links with this icon indicate that you are leaving the CDC website.
- The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
- Linking to a non-federal Website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
- You will be subject to the destination website's privacy policy when you follow the link.
- CDC is not responsible for Section 508 compliance (accessibility) on other federal or private websites.